Main menu

Isis Pharmaceuticals this week announced that the US Food and Drug Administration has fast tracked its antisense-based transthyretin amyloidosis drug ISIS-TTRRx for use in patients with familial amyloid polyneuropathy, the rarer form of the disease.

The drug is being developed by Isis in collaboration with GlaxoSmithKline. A phase II/III study is expected to start this month, triggering a $7.5 million milestone payment from GlaxoSmithKline, Isis said.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.